The first paper on CRISPR gene editing tech was only published in 2012. As a key player in the biotech revolution, CRISPR is the discovery of the century, permitting a whole new field of gene-editing for therapeutic purposes in a range of different research areas.
Two of those responsible for the existence of CRISPR-Cas9, Jennifer Doudna from UC Berkeley and Emmanuelle Charpentier, now based in Berlin at the Max Planck Institute, have surprisingly not won the Nobel Prize for Chemistry, despite Reuter’s prediction.
The categorization of Nobel Prizes has often been slightly blurred, with many key biomedical discoveries also being awarded the Chemistry prize. The announcement for the prize in Chemistry comes just two days after the joint-award for the Nobel prize in Medicine & Physiology, which went to the discoverers of ivermectin and artemisinin, two medicines for parasitic diseases.
But the prize has gone instead to Thomas Lindahl,